Changes in Hong Kong stocks | Collumbotai Bio-B (06990) rose more than 4% ITGB6 and two drug candidates will launch phase I/II single-drug treatment clinical trials in the first quarter of next year

The Zhitong Finance App learned that Columbite Biotech (06990) rose more than 4%. As of press release, it had risen 3.69% to HK$427.4, with a turnover of HK$183.16,900.

According to the news, recently, Columbotai Biotech and Crescent reached a cooperation to jointly develop and commercialize novel tumor treatment methods (including novel combination therapies), involving SKB105 (CR-003), an ADC drug with targeted integrin beta-6 (ITGB6) and a topoisomerase inhibitor loaded with a topoisomerase inhibitor, and Crescent's PD-1XVEGF bispecific antibody CR-001 (SKB118). These two drug candidates are being developed to treat solid tumors, and phase I/II single-agent clinical trials are expected to be conducted in the first quarter of 2026.

Tianfeng Securities pointed out that the cooperation between Collenbotai Biotech and Crescent includes separately promoting the development of monotherapy with two drug candidates and jointly evaluating the combination therapy of CR-001 and SKB105. Both parties have the right to independently develop other joint solutions for CR-001. CR-001 is a quadrivalent bispecific antibody that has shown strong anti-tumor activity in preclinical studies.

In terms of consideration, Colombotech will receive an initial payment of $80 million from Crescent and will be eligible for a cumulative milestone payment of up to $1.25 billion, as well as tiered royalties based on SKB105's net sales that fluctuate in a medium to low double digit ratio. If Crescent recently changed control or entered into a licensing arrangement with a third party, Collumbotai Biotech is also eligible to receive additional consideration.